Santen Buys Asia, Europe Rights To Merck's Eye Drugs For $600 Million
This article was originally published in PharmAsia News
Executive Summary
Santen Pharmaceutical has licensed eye drugs from Merck for $600 million upfront, plus milestone payments and royalties, to market them in the Asia Pacific region and in Europe.